<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669133</url>
  </required_header>
  <id_info>
    <org_study_id>1807274844</org_study_id>
    <nct_id>NCT03669133</nct_id>
  </id_info>
  <brief_title>Vitamin E for NASH Treatment in HIV Infected Individuals</brief_title>
  <official_title>Vitamin E for NASH Treatment in HIV Infected Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see how taking Vitamin E daily affects fatty liver in persons
      living with HIV. Subjects will have both HIV and a fatty liver and the purpose of the study
      is to learn if underlying liver condition (fatty liver) gets better, worse, or stays the same
      from taking Vitamin E.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will conduct a proof-of-concept clinical trial to evaluate the efficacy of
      vitamin E for treatment of non-alcoholic steatohepatitis (NASH) in persons living with HIV.
      Hypothesis: Vitamin E will improve radiographically measured hepatic fat content and
      circulating markers of liver inflammation and injury in persons living with HIV who have
      NASH.

      A. Perform a pilot randomized placebo controlled trial of vitamin E 800 IU/daily for 6 months
      in 56 persons living with HIV with biopsy-proven NASH B. Measure change in liver fat content
      by magnetic resonance proton-density fat fraction (Primary outcome) C. Determine the impact
      of vitamin E treatment on noninvasive markers of hepatic and systemic inflammation, hepatic
      fibrosis, and systemic oxidative stress (Secondary outcomes) D. Define baseline hepatic gene
      expression signatures predictive of response to therapy.

      Upon completion, the proposed clinical trial may establish vitamin E as an excellent and
      inexpensive candidate for further development as a treatment for NASH in persons living with
      HIV.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group A: Vitamin E 800 IU/daily for 24 weeks. (total of 28 subjects) Group B: Matching placebo for 24 weeks (total of 28 subjects)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Study biostatistician and Investigational Drug Services pharmacist will randomize subjects and will provide study drug</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Measure % change in liver fat content by magnetic resonance proton-density fat fraction</measure>
    <time_frame>at randomization visit (study day 1) and end of study visit (week 24)</time_frame>
    <description>MRI at randomization and completion visits to assess liver steatosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the impact of vitamin E treatment on noninvasive markers of hepatic inflammation</measure>
    <time_frame>at randomization visit (study day 1) and end of study visit (week 24)</time_frame>
    <description>ALT(IU/L), AST (IU/L) , cytokeratin-18 (IU/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the impact of vitamin E treatment on noninvasive markers of systemic inflammation</measure>
    <time_frame>at randomization visit (study day 1) and end of study visit (week 24)</time_frame>
    <description>TNF-alpha (pg/L), IL-10 (pg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the impact of vitamin E treatment on noninvasive markers of hepatic fibrosis</measure>
    <time_frame>at randomization visit (study day 1) and end of study visit (week 24)</time_frame>
    <description>liver stiffness by fibroscan (kPa)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>NAFLD</condition>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin E 800 IU/daily for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin E</intervention_name>
    <description>Vitamin E 800 IU/daily</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Matching placebo daily</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. males and females ≥18 years with biopsy-proven NASH within 6 months prior to
             enrollment

          2. histological diagnosis of NASH will be confirmed by an experienced liver pathologist
             before study entry

          3. HIV infection

          4. stable dose of anti-diabetic agents and ART in the 3 months preceding enrollment and
             expected by the physician treating diabetes and HIV to remain on stable medications
             during the study

          5. willingness to participate in the study

          6. ability to understand and give informed consent for participation

        Exclusion Criteria:

          1. Presence of other chronic liver diseases (hepatitis B or C, autoimmune hepatitis,
             cholestatic liver disease, Wilson disease, hemochromatosis, etc.)

          2. average alcohol consumption &gt;3 drinks/day for men or &gt;2 drinks/day for women in the 6
             months prior to enrollment.

          3. Alcohol Use Disorder Identification Test (AUDIT) score of ≥8

          4. evidence of cirrhosis on histology or imaging

          5. ongoing use of medications known to cause hepatic steatosis (e.g., corticosteroids,
             amiodarone, methotrexate, tetracycline, tamoxifen, estrogens at doses greater than
             those used for birth control, anabolic steroids, or valproic acid)

          6. prior bariatric surgery

          7. severe co-morbidities (e.g., advanced cardiac, renal, pulmonary, or psychiatric
             illness)

          8. allergy to vitamin E

          9. use of vitamin E or multivitamins containing vitamin E in the three months preceding
             enrollment

         10. use of drugs with potential effect on NASH such as ursodeoxycholic acid,
             S-adenosylmethionine (SAM-e), betaine, pentoxifylline, or milk thistle in the three
             months prior to enrollment.

         11. changing doses of statins (simvastatin, pravastatin, atorvastatin, fluvastatin,
             lovastatin, rosuvastatin) or fibrates (clofibrate, fenofibrate) in the three months
             prior enrollment.

         12. illicit substance abuse within the past twelve months

         13. breast feeding, pregnancy, inability or unwillingness to practice contraception for
             the duration of the study

         14. contraindications for the MRI procedure (e.g., prostheses, severe claustrophobia)

         15. poorly controlled diabetes with A1C &gt;8.5 within in the last six months

         16. use of total parenteral nutrition in the 6 months preceding liver biopsy or enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Samer Gawrieh, MD</last_name>
    <phone>317-278-9326</phone>
    <email>sgawrieh@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Regina Weber, BS, RRT</last_name>
    <phone>317-278-3584</phone>
    <email>reginaw@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Montreca Robison</last_name>
      <phone>317-278-0408</phone>
      <email>mgrobiso@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Regina Weber, BS, RRT</last_name>
      <phone>317-278-3584</phone>
      <email>reginaw@iu.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen E Corey, MD</last_name>
      <email>Kathleen.Corey@MGH.HARVARD.EDU</email>
    </contact>
    <contact_backup>
      <last_name>Jenna L Gustafson</last_name>
      <phone>(617)724-3836</phone>
      <email>jlgustafson@partners.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>December 18, 2019</last_update_submitted>
  <last_update_submitted_qc>December 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University School of Medicine</investigator_affiliation>
    <investigator_full_name>Samer Gawrieh</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Fatty liver</keyword>
  <keyword>NAFLD</keyword>
  <keyword>NASH</keyword>
  <keyword>HIV</keyword>
  <keyword>Vitamin E</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin E</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

